Fortress Biotech
company
Nasdaq
SEC CIK 1429260 LEI 529900DZUWSYUURECK24
Follow Fortress Biotech
Weekly email: filings, results
Revenue, last quarter
$19.2M
+8.7% vs same quarter last year
Net income
−$5.8M
−199.9% vs same quarter last year
EPS, diluted
−$0.23
−309.1% vs same quarter last year
Operating cash flow
−$6.2M
−1.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $63.3M | - |
| FY24 | $57.7M | - |
| FY23 | $84.5M | - |
| FY22 | $75.7M | −$86.6M |
| FY21 | $68.8M | −$64.7M |
| FY20 | $45.6M | −$46.5M |
| FY19 | $36.6M | −$40M |
| FY18 | $26.9M | −$84.1M |
| FY17 | $17.2M | −$66.9M |
| FY16 | $16.5M | −$55.1M |
| FY15 | $863K | −$48.4M |
| FY14 | $0 | −$20.4M |
| FY13 | $0 | −$37.2M |
| FY12 | - | −$27.6M |
| FY11 | - | −$36.4M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 66.9% | −111% | - |
| FY24 | 63.8% | −191.4% | - |
| FY23 | 72.9% | −168.4% | - |
| FY22 | 59.4% | −268.8% | −114.3% |
| FY21 | 53.4% | −274.1% | −94.1% |
| FY20 | 68% | −206.7% | −102% |
| FY19 | 71.2% | −302.5% | −109.1% |
| FY18 | 77.2% | −446.4% | −313% |
| FY17 | 78.8% | −520.7% | −387.8% |
| FY16 | 95.2% | −398.7% | −334.3% |
| FY15 | 100% | −5855.3% | −5611.6% |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | - | - |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | −$80.2M |
| FY23 | −$128.3M |
| FY22 | −$182.1M |
| FY21 | −$121.1M |
| FY20 | −$85.6M |
| FY19 | −$97.3M |
| FY18 | −$105.9M |
| FY17 | −$82M |
| FY16 | −$52.2M |
| FY15 | −$20.7M |
| FY14 | −$16.3M |
| FY13 | −$29.7M |
| FY12 | −$23.2M |
| FY11 | −$11M |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | $664K | - |
| FY24 | $694K | - |
| FY23 | $736K | - |
| FY22 | $749K | - |
| FY21 | $749K | - |
| FY20 | $237K | $70K |
| FY19 | $0 | $0 |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | - | - |
| FY11 | - | - |
- Fortress Biotech
- Healthcare median
Show the numbers
| Year | Fortress Biotech | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | −114.3% | −80.4% |
| FY21 | −94.1% | −71.8% |
| FY20 | −102% | −62.2% |
| FY19 | −109.1% | −46.2% |
| FY18 | −313% | −49.6% |
| FY17 | −387.8% | −45.9% |
| FY16 | −334.3% | −36% |
| FY15 | −5611.6% | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |